Amanta Healthcare Limited — Investor Meet, 21-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Amanta Healthcare held a Q4 FY26 earnings conference call to discuss financial performance and business outlook. Management expressed confidence in the company's strategic foundation and growth prospects, highlighting disciplined execution and progress in strengthening its core business.

**Financial Performance:**

* FY26 revenue reached INR288 crore, a 5% YoY increase.

* EBITDA stood at INR63 crore with a stable margin of 22%.

* PAT grew significantly by over 42% YoY to INR15 crore for FY26, with PAT margin expanding to 5%.

* Q4 FY26 revenue was INR77 crore, up 6.8% YoY.

**Management Commentary & Outlook:**

* Focus remains on strengthening the core business, improving profitability, and enhancing operational efficiencies for future growth.

* The SteriPort platform, utilizing advanced ISBM technology, contributes ~42% of revenue. Capacity is being expanded from 6.6 Cr to 12 Cr bottles annually to capture growing market demand for two-port IV fluid systems.

* SVP portfolio expansion in inhalation solutions and preservative-free ophthalmics is underway, targeting high-value segments.

* Balance sheet strengthening continues with a reduced debt-to-equity ratio of ~1x.

* A 10.8 MW captive solar power project is nearing commissioning, expected to reduce power costs from FY27.

* Priorities for FY27 include enhancing regulatory approvals, developing product pipeline (20 products currently), expanding export opportunities, driving operational efficiencies, and maintaining financial prudence.

**Operational Updates:**

* The SteriPort capacity expansion is expected to be operational by June 20.

* Solar power project expected to commission by end-May.

**Analyst Q&A Highlights:**

* Management addressed concerns regarding raw material price increases (plastic prices up 60-70%), stating price revisions have been implemented with minimal resistance, particularly for SteriPort.

* They anticipate the SteriPort line to contribute INR80-85 crore in its first three quarters (FY27), with full impact in the following year.

* SteriPort EBITDA margins are projected at ~27%, leading to an overall blended EBITDA margin of 24-25% going forward.

* PAT margins are expected to improve disproportionately due to reduced finance costs and operating leverage.

* Exports formed 39% of revenue in FY26, with key markets including Thailand, UK, Philippines, and South Sudan.

* Contract manufacturing currently accounts for ~8-10% of revenue.

**Investor Angle:**

The company presented a solid financial performance for FY26, driven by operational discipline and improved profitability. The ongoing capacity expansion for the key SteriPort product, coupled with cost efficiency initiatives like the solar project, positions Amanta Healthcare for future growth. Management's focus on a differentiated product mix and financial prudence signals a confident outlook.